Status: Recruiting
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.
Participants needed: 13
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou Xiling Biotechnology Co., Ltd.Updated: Dec 2, 2025Locations: 1
Eligibility criteria
Age ≥ 18 years old, gender not limited; [+19]
Individuals allergic to any component of CEL001 injection, including those aller... [+14]